# Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes

> **NCT01189422** · PHASE1 · TERMINATED · sponsor: **MacroGenics** · enrollment: 1 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** teplizumab or placebo

## Key facts

- **NCT ID:** NCT01189422
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189422, "Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01189422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*